Ella Hohmann, MS

Claims data linked eviction protection rollbacks to higher psychotropic prescription and SMI visits, revealing housing security’s mental health toll.

Rising ER-positive breast cancer in young women: risk factors, subtype differences, and when to push for screening and imaging.

Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.

Private equity reshapes care—new evidence links staffing cuts to patient safety risks; ACP urges regulatory oversight to defend clinical autonomy.

A new training framework operationalizes brachytherapy competencies for soft tissue sarcoma, covering implant geometry, CT planning, dose optimization, toxicity management, and radiation safety.

Endometriosis is often mistaken for IBS, fibroids, UTIs, PID, and ovarian cysts, potentially delaying diagnosis, treatment, and fertility care for years.

The FDA approves Datroway for first-line metastatic triple-negative breast cancer in immunotherapy-ineligible patients.

From hypofractionation to proton beam therapy to pembrolizumab combinations, a new review details how 2025 reshaped the radiotherapy landscape for soft tissue sarcomas.

Breast cancer incidence climbs in young women under 40 and risk-based screening earlier may help reduce this, explains Rani Bansai, MD.

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk after, reshaping care.

New pediatric guidelines standardize radiation for metastatic rhabdomyosarcoma, detailing site-specific dosing to improve STS outcomes.

Global experts have renamed PCOS to PMOS, highlighting metabolic and endocrine risks—here’s what the name change means for diagnosis and care.

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

Deep learning model beats breast density for 5-year breast cancer risk, informing supplemental screening decisions and personalized care.

Fears that the telemedicine boom would send health care costs soaring haven’t been borne out, a major new study finds, and the timing couldn’t be more critical for federal policy makers.

New review maps how endometriosis hijacks glucose, lipid, and amino acid metabolism to fuel lesion survival, immune evasion, and infertility.

Health-system specialty pharmacies leverage EHR insights to enhance real-world evidence, improve access, and streamline prior authorizations.

New soft tissue sarcoma radiotherapy guidelines favor preoperative radiotherapy, refine dosing and targeting, and preview the role of immunotherapy and hypofractionation.

Amid breast cancer surging in women under 50, new data and WISDOM trial results support individualized screening over age-based guidelines.

Fatima Cody Stanford, MD, MPH, MPA, exposes obesity health disparities, GLP-1 access hurdles, payer policy fixes, and how stigma in care blocks equitable treatment.

This FDA approval brings the first heterobifunctional protein degrader for HER2-negative, ESR1-mutant breast cancer, improving PFS after endocrine therapy.

Fatima Cody Stanford, MD, MPH, MPA, breaks down the brain mechanisms behind obesity and how to empower patients and improve clinical outcomes.

Rani Bansal, MD, discusses breast cancer subtypes, racial disparities in triple-negative disease, self-advocacy for young patients, and diversity in clinical trials.

The therapy receives FDA approval for Alzheimer disease agitation, backed by phase 3 data showing significant symptom reduction and delayed relapse vs placebo.

Experts at AXS26 laid out why advanced therapies are underutilized and what payers, providers, and manufacturers must do together to change that.

At NAACOS 2026, value-based care leaders make the case for treating payers as partners and explain what providers must see in return.

Rani Bansal, MD, explores what's driving the surge in breast cancer in young women and why earlier, risk-based screening matters.

Discussion covered lung cancer biomarker testing, care in hematologic malignancies, health equity in cancer screening, and medically integrated pharmacy dispensing

A new AHIP report outlines evidence-based strategies to cut chronic disease prevalence by 10% by 2035.